{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:37:21Z","timestamp":1794260241424,"version":"4.9.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Antibiot."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate the <jats:italic>in vitro<\/jats:italic> antimicrobial susceptibilities of Gram-positive and Gram-negative isolates from patients in Jordan between 2010 and 2021, through the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Medical centres in Jordan collected bacterial isolates from hospitalised patients with defined infection sources between 2010 and 2021 (no isolates collected in 2014). Antimicrobial susceptibility was interpreted using CLSI standards. FDA-approved breakpoints were applied for tigecycline. The identification of \u03b2-lactamase genes was performed for a proportion of isolates using multiplex PCR assays.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>More than 92% of <jats:italic>Acinetobacter baumannii<\/jats:italic> collected were multidrug-resistant (MDR) and\/or carbapenem-resistant (CR), and &amp;gt; 50% susceptibility was reported only to minocycline (62.2% among both MDR and CR isolates). Rates of MDR and CR <jats:italic>Pseudomonas aeruginosa<\/jats:italic> were 14.3% and 20.5%, respectively, and among all <jats:italic>P. aeruginosa<\/jats:italic> collected from adults, susceptibility to ceftazidime\/avibactam was 95.3% and to ceftolozane\/tazobactam was 88.4%. For <jats:italic>Escherichia coli<\/jats:italic> from adults and MDR <jats:italic>E. coli<\/jats:italic>, susceptibility to ceftazidime\/avibactam, ceftolozane\/tazobactam, imipenem, meropenem and meropenem\/vaborbactam was 92.1%\u201398.7%. Susceptibility to tigecycline was &amp;gt; 94% among <jats:italic>Klebsiella pneumoniae<\/jats:italic> from adult, paediatric, and ICU patients (all ages). CTX-M-15 was the most frequently identified \u03b2-lactamase gene among <jats:italic>E. coli<\/jats:italic> and <jats:italic>K. pneumoniae<\/jats:italic>. Susceptibility to most antimicrobial agents was &amp;lt; 50% among <jats:italic>K. pneumoniae<\/jats:italic> carrying CTX-M-15, CTX-M-9-type, NDM-5, and\/or OXA-48 \u03b2-lactamase genes. All <jats:italic>S. aureus<\/jats:italic> collected were susceptible to teicoplanin, vancomycin, daptomycin, linezolid and tigecycline, with 96.1% of <jats:italic>S. aureus<\/jats:italic> from adults were susceptible to ceftaroline. Overall, 58.8% of <jats:italic>Staphylococcus aureus<\/jats:italic> were MRSA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provides valuable information regarding antimicrobial susceptibility in Jordan between 2010 and 2021. Continued monitoring of <jats:italic>in vitro<\/jats:italic> antimicrobial susceptibility is critical in the fight against antimicrobial resistance.<\/jats:p><\/jats:sec>","DOI":"10.3389\/frabi.2024.1375980","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T12:33:43Z","timestamp":1723120423000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["In vitro antimicrobial susceptibility of clinical isolates from adult and paediatric patients in Jordan: Antimicrobial Testing Leadership and Surveillance (ATLAS) 2010\u20132021"],"prefix":"10.3389","volume":"3","author":[{"given":"Dima","family":"Al Jammal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bachir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihane A.","family":"Moussa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal Wadi","family":"Al Ramahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3823\/852","article-title":"Susceptibility of the multidrug-resistant nosocomial pathogens isolates in Jordan for the new antimicrobial agents","volume":"11","author":"Al Ramahi","year":"2021","journal-title":"Int. Arabic. J. Antimicrobial. Agents"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab159","article-title":"Evaluation of the in vitro activity of ceftaroline, ceftazidime\/avibactam and comparator antimicrobial agents against clinical isolates from paediatric patients in Kuwait: ATLAS data 2012\u201319","volume":"3","author":"Al-Sweih","year":"2021","journal-title":"JAC. Antimicrob. Resist."},{"key":"B3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"B4","unstructured":"2023"},{"key":"B5","unstructured":"2023"},{"key":"B6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jiph.2016.02.002","article-title":"Detection of OXA-48-like and NDM carbapenemases producing Klebsiella pneumoniae in Jordan: A pilot study","volume":"10","author":"Aqel","year":"2017","journal-title":"J. Infect. Public Health"},{"key":"B7","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.1128\/AAC.00206-15","article-title":"In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013","volume":"59","author":"Biedenbach","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1128\/AAC.45.8.2269-2275.2001","article-title":"Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240\u2192Gly","volume":"45","author":"Bonnet","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"B9","volume-title":"Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Eleventh Informational Supplement M07-S11.","year":"2018"},{"key":"B10","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: Thirty-Third Informational Supplement M100-S33","year":"2023"},{"key":"B11","doi-asserted-by":"publisher","first-page":"FSO438","DOI":"10.2144\/fsoa-2019-0098","article-title":"A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options","volume":"6","author":"Elshamy","year":"2020","journal-title":"Future Sci. OA"},{"key":"B12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jgar.2020.08.004","article-title":"In vitro activity of aztreonam\/avibactam against a global collection of Klebsiella pneumoniae collected from defined culture sources in 2016 and 2017","volume":"24","author":"Esposito","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01406-22","article-title":"Epidemiology of resistance determinants identified in meropenem-nonsusceptible Enterobacterales collected as part of a global surveillance study 2018 to 2019","volume":"67","author":"Estabrook","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-\u03b2-lactamase-producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"B15","unstructured":"Tigecycline \u2013 Injection products2023"},{"key":"B16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ijid.2015.04.011","article-title":"Susceptibility trends and molecular characterization of Gram-negative bacilli associated with urinary tract and intra-abdominal infections in Jordan and Lebanon: SMART 2011-2013","volume":"35","author":"Hayajneh","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlab067","article-title":"In vitro activity of ceftazidime\/avibactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa from Middle Eastern and African countries: ATLAS global surveillance programme 2015-18","volume":"3","author":"Karlowsky","year":"2021","journal-title":"JAC. Antimicrob. Resist."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlac060","article-title":"Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa causing infection in Africa and the Middle East: a surveillance study from the ATLAS programme, (2018-20)","volume":"4","author":"Karlowsky","year":"2022","journal-title":"JAC. Antimicrob. Resist."},{"key":"B19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jgar.2020.12.013","article-title":"In vitro activity of ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in the Middle East and Africa: AWARE global surveillance programme 2015\u20132018","volume":"24","author":"Karlowsky","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e00592","DOI":"10.1128\/AAC.00592-18","article-title":"In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program from 2012 to 2015","volume":"62","author":"Kazmierczak","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ijid.2022.10.014","article-title":"Activity of ceftolozane\/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa \u2013Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020","volume":"125","author":"Lob","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1128\/AAC.05186-14","article-title":"Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program 2009 to 2013","volume":"59","author":"Lob","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.1128\/JCM.43.7.3309-3313.2005","article-title":"Countrywide spread of community- and hospital-acquired extended-spectrum beta-lactamase (CTX-M-15)-producing Enterobacteriaceae in Lebanon","volume":"43","author":"Moubareck","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"B24","unstructured":"Phase 3 studies of Pfizer\u2019s novel antibiotic combination offer new treatment hope for patients with multidrug-resistant infections and limited treatment options2023"},{"key":"B25","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s12879-021-06153-0","article-title":"In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators, (2016-2018)","volume":"21","author":"Pi\u00e9rard","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/jac\/dkf240","article-title":"Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3","volume":"50","author":"Poirel","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10040393","article-title":"Antibiotic resistance in pediatric infections: global emerging threats, predicting the near future","volume":"10","author":"Romandini","year":"2021","journal-title":"Antibiot. (Basel)."},{"key":"B28","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"B29","unstructured":"Fact sheets: Antimicrobial resistance2021"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa651","article-title":"Meta-analysis of clinical outcomes using ceftazidime\/avibactam, ceftolozane\/tazobactam, and meropenem\/vaborbactam for the treatment of multidrug-resistant Gram-negative infections","volume":"8","author":"Wilson","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s10096-023-04645-2","article-title":"In vitro activity of aztreonam-avibactam against Enterobacterales isolates collected in Latin America, Africa\/Middle East, Asia, and Eurasia for the ATLAS Global Surveillance Program in 2019-2021","volume":"42","author":"Wise","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."}],"container-title":["Frontiers in Antibiotics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frabi.2024.1375980\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T12:34:12Z","timestamp":1723120452000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frabi.2024.1375980\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":31,"alternative-id":["10.3389\/frabi.2024.1375980"],"URL":"https:\/\/doi.org\/10.3389\/frabi.2024.1375980","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/frabi.2024.1375980.s001","asserted-by":"subject"}]},"ISSN":["2813-2467"],"issn-type":[{"value":"2813-2467","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,8]]},"article-number":"1375980"}}